How does one assess early rheumatoid arthritis in daily clinical practice?

In past years, consensus has been reached on the assessment of rheumatoid arthritis in clinical trials. Next to a core set of disease activity variables, response criteria have been developed and validated. These criteria are, however, of limited value in daily clinical practice. In this situation, emphasis should be paid to accurate measurement of disease activity on a continuous scale using the lowest possible number of core set variables. Different studies have shown that the DAS28 is a valuable instrument for this purpose. Many factors have been identified to possess a prognostic value; however, the IgM rheumatoid factor is still the only one which is of any importance in daily clinical practice.

[1]  N. Milman,et al.  Inflammatory patterns in rheumatoid arthritis estimated by the number of swollen and tender joints, the erythrocyte sedimentation rate, and hemoglobin: longterm course and association to radiographic progression. , 2000, The Journal of rheumatology.

[2]  A. Silman,et al.  Inflammatory polyarthritis in the community is not a benign disease: predicting functional disability one year after presentation. , 1996, The Journal of rheumatology.

[3]  Lars Klareskog,et al.  Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study , 1998, BMJ.

[4]  R. Beckenbaugh,et al.  Tissue cytokine patterns distinguish variants of rheumatoid synovitis. , 1997, The American journal of pathology.

[5]  H. Schumacher,et al.  Clinical assessment of the 1987 American College of Rheumatology criteria for rheumatoid arthritis. , 1996, Scandinavian journal of rheumatology.

[6]  M. Leirisalo-Repo,et al.  The prognostic value of HLA DR4 and B27 antigens in early rheumatoid arthritis. , 1993, Scandinavian journal of rheumatology.

[7]  J J Anderson,et al.  The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials , 1993 .

[8]  T. Möttönen,et al.  Prediction of erosiveness and rate of development of new erosions in early rheumatoid arthritis. , 1988, Annals of the rheumatic diseases.

[9]  A. Zwinderman,et al.  Factors predicting outcome of rheumatoid arthritis: results of a followup study. , 1993, The Journal of rheumatology.

[10]  D. Felson,et al.  ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology. , 1999, The Journal of rheumatology.

[11]  J. Rasker,et al.  Cause and age at death in a prospective study of 100 patients with rheumatoid arthritis. , 1981, Annals of the rheumatic diseases.

[12]  M. Prevoo,et al.  Validity and reliability of joint indices. A longitudinal study in patients with recent onset rheumatoid arthritis. , 1993, British journal of rheumatology.

[13]  F. Breedveld,et al.  Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. , 1995, Arthritis and rheumatism.

[14]  A. Woolf,et al.  Predictors of the long-term outcome of early synovitis: a 5-year follow-up study. , 1991, British journal of rheumatology.

[15]  V. Gersuk,et al.  HLA-DRB1 typing in rheumatoid arthritis: predicting response to specific treatments , 1998, Annals of the rheumatic diseases.

[16]  J. Anderson,et al.  The rapid assessment of disease activity in rheumatology (radar) questionnaire. Validity and sensitivity to change of a patient self-report measure of joint count and clinical status. , 1992, Arthritis and rheumatism.

[17]  M. Prevoo,et al.  Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. , 1996, Arthritis and rheumatism.

[18]  M. Prevoo,et al.  Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. , 1996, British journal of rheumatology.

[19]  K. Eberhardt,et al.  HLA-DR antigens, Gm allotypes and antiallotypes in early rheumatoid arthritis--their relation to disease progression. , 1993, The Journal of rheumatology.

[20]  J. Sharp.  Preliminary criteria for remission in rheumatoid arthritis. , 1982, Arthritis and rheumatism.

[21]  T. Pincus,et al.  ACR 20: clinical or statistical significance? , 1999, Arthritis and rheumatism.

[22]  H. Huhtala,et al.  ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS , 2000 .

[23]  T. Pincus,et al.  A simplified twenty-eight-joint quantitative articular index in rheumatoid arthritis. , 1989, Arthritis and rheumatism.

[24]  H. Fuchs.  The use of the disease activity score in the analysis of clinical trials in rheumatoid arthritis. , 1993, The Journal of rheumatology.

[25]  Paul Wordsworth,et al.  Genetic typing of patients with inflammatory arthritis at presentation can be used to predict outcome. , 1994, Arthritis and rheumatism.

[26]  A. Silman,et al.  Factors predicting death, survival and functional outcome in a prospective study of early rheumatoid disease over fifteen years. , 1993, British journal of rheumatology.

[27]  D. Mitchell,et al.  Preliminary criteria for clinical remission in rheumatoid arthritis. , 1981, Arthritis and rheumatism.

[28]  P. van Riel,et al.  Long-Term Usage and Side-Effect Profile of Sulphasalazine in Rheumatoid Arthritis , 1995 .

[29]  Richard W. Martin,et al.  A PHASE III TRIAL OF ETANERCEPT vs METHOTREXATE (MTX) IN EARLY RHEUMATOID ARTHRITIS (ENBREL ERA TRIAL) , 2000 .

[30]  M. Liang,et al.  A self-administered rheumatoid arthritis disease activity index (RADAI) for epidemiologic research. Psychometric properties and correlation with parameters of disease activity. , 1995, Arthritis and rheumatism.

[31]  F. Wolfe,et al.  The assessment and prediction of functional disability in rheumatoid arthritis. , 1991, The Journal of rheumatology.

[32]  D. Furst,et al.  Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. , 1989, The Journal of rheumatology.

[33]  J. Woody,et al.  Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis , 1994, The Lancet.

[34]  D. Mosher,et al.  Self-assessment of disease activity by patients with rheumatoid arthritis. , 1996, The Journal of rheumatology.

[35]  C. Weyand,et al.  Homozygosity for the HLA-DRB1 allele selects for extraarticular manifestations in rheumatoid arthritis. , 1992, The Journal of clinical investigation.

[36]  M. Prevoo,et al.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[37]  G. Stucki,et al.  Feasibility and validity of the RADAI, a self-administered rheumatoid arthritis disease activity index. , 2000, Rheumatology.

[38]  V. Strand,et al.  Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis , 1995 .

[39]  van der Heijde Dm,et al.  Validity of single variables and indices to measure disease activity in rheumatoid arthritis. , 1993 .

[40]  P. Riel.  PROVISIONAL GUIDELINES FOR MEASURING DISEASE ACTIVITY IN CLINICAL TRIALS ON RHEUMATOID ARTHRITIS , 1992 .

[41]  M Yaron,et al.  Sleep disturbances, fibromyalgia and primary Sjögren's syndrome. , 1997, Clinical and experimental rheumatology.

[42]  H. Huhtala,et al.  Antineutrophil cytoplasmic antibodies in patients with early rheumatoid arthritis: an early marker of progressive erosive disease. , 2000, Arthritis and rheumatism.

[43]  E. Tindall,et al.  Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. , 1997, The New England journal of medicine.

[44]  J. Fries,et al.  The development of disability in rheumatoid arthritis. , 1986, Arthritis and rheumatism.

[45]  P. van Riel,et al.  Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. , 1998, Arthritis and rheumatism.

[46]  M. V. van Leeuwen,et al.  PROGNOSTIC FACTORS FOR RADIOGRAPHIC DAMAGE AND PHYSICAL DISABILITY IN EARLY RHEUMATOID ARTHRITIS. A PROSPECTIVE FOLLOW-UP STUDY OF 147 PATIENTS , 1992 .

[47]  P. Geborek,et al.  Clinical protocol for monitoring of targeted therapies in rheumatoid arthritis. , 2000, Rheumatology.

[48]  M. Prevoo,et al.  Validity and reproducibility of self-administered joint counts. A prospective longitudinal followup study in patients with rheumatoid arthritis. , 1996, The Journal of rheumatology.

[49]  C. Weyand,et al.  The Influence of HLA-DRB1 Genes on Disease Severity in Rheumatoid Arthritis , 1992, Annals of Internal Medicine.

[50]  M. A. van 't Hof,et al.  Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. , 1990, Annals of the rheumatic diseases.

[51]  M. V. van Leeuwen,et al.  The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. , 2000, Arthritis and rheumatism.

[52]  G. Wells,et al.  Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? , 1998, Arthritis and rheumatism.

[53]  M. V. van Leeuwen,et al.  Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants. , 1994, The Journal of rheumatology.

[54]  B. Combe,et al.  Anti-Sa antibody is an accurate diagnostic and prognostic marker in adult rheumatoid arthritis. , 1999, The Journal of rheumatology.

[55]  M. Hochberg.  Early aggressive DMARD therapy: the key to slowing disease progression in rheumatoid arthritis. , 1999, Scandinavian journal of rheumatology. Supplement.

[56]  J J Anderson,et al.  American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. , 1995, Arthritis and rheumatism.